MARKET

CDTX

CDTX

Cidara Theraptcs
NASDAQ
0.6081
+0.0580
+10.54%
Closed 16:00 10/04 EDT
OPEN
0.5757
PREV CLOSE
0.5501
HIGH
0.6449
LOW
0.5500
VOLUME
700.59K
TURNOVER
--
52 WEEK HIGH
2.200
52 WEEK LOW
0.4000
MARKET CAP
42.61M
P/E (TTM)
-0.5614
1D
5D
1M
3M
1Y
5Y
Cidara Therapeutics receives $11.1M milestone payment from Mundipharma
Cidara Therapeutics (NASDAQ:CDTX) has <a href="https://seeking...
Seekingalpha · 1d ago
Cidara spikes on $11M milestone payment from partner Mundipharma
The shares of clinical-stage biotech Cidara Therapeutics (NASDAQ:C...
Seekingalpha · 1d ago
Cidara Therapeutics Receives $11.1M Milestone Payment from Mundipharma; Payment Triggered By European Medicines Agency Acceptance Of Marketing Authorization Application For Rezafungin
Company eligible to receive up to an additional $108M in milestones from multiple existing partnerships based on successful completion of activities planned for the next two years SAN DIEGO, Oct. 04, 2022
Benzinga · 1d ago
Cidara Therapeutics Gets $11 Million Milestone Payment From Mundipharma
Cidara Therapeutics Gets $11 Million Milestone Payment From Mundipharma
MT Newswires · 1d ago
Cidara's Lead Antifungal Candidate Goes Under Priority FDA Review
Benzinga · 09/21 14:27
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers CinCor Pharma (NASDAQ:CINC) shares moved upwards by 19.5% to $33.0 during Tuesday&#39;s after-market session. The market value of their outstanding shares is at $1.4 billion.
Benzinga · 09/20 21:35
Cidara Therapeutics Announces FDA Acceptance For Priority Review Of New Drug Application For Rezafungin For The Treatment Of Candidemia And Invasive Candidiasis
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and
Benzinga · 09/20 20:08
BRIEF-Cidara Therapeutics Announces FDA Acceptance For Priority Review Of New Drug Application For Rezafungin
BRIEF-Cidara Therapeutics Announces FDA Acceptance For Priority Review Of New Drug Application For Rezafungin
Reuters · 09/20 20:07
More
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The Company's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.

Webull offers kinds of Cidara Therapeutics Inc stock information, including NASDAQ:CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDTX stock methods without spending real money on the virtual paper trading platform.